Brokers Issue Forecasts for KYTX FY2027 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Research analysts at HC Wainwright issued their FY2027 earnings estimates for shares of Kyverna Therapeutics in a report issued on Monday, March 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($2.67) for the year. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share.

A number of other research firms also recently commented on KYTX. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Wells Fargo & Company raised their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.67.

Kyverna Therapeutics Trading Down 2.8%

Shares of Kyverna Therapeutics stock opened at $7.58 on Tuesday. The stock has a 50 day moving average of $8.27 and a 200 day moving average of $7.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.75 and a current ratio of 7.75. The firm has a market capitalization of $332.00 million, a price-to-earnings ratio of -2.08 and a beta of 3.31. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Kyverna Therapeutics in the third quarter valued at $28,000. Capital Advisors Inc. OK purchased a new stake in shares of Kyverna Therapeutics in the 3rd quarter valued at $60,000. EntryPoint Capital LLC acquired a new position in Kyverna Therapeutics during the 4th quarter worth about $94,000. Phoenix Wealth Advisors lifted its stake in Kyverna Therapeutics by 17.1% during the 4th quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock worth $116,000 after acquiring an additional 1,800 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Kyverna Therapeutics during the 3rd quarter valued at about $77,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.